Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses

BACKGROUND: Immuno-oncology, and in particular, check-point inhibitors (CPIs), have led to a paradigm shift in the field of cancer care. The cost of new drug development is high, and many novel agents in oncology are significantly more expensive than older agents. Therefore, healthcare funders have...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ying, Camateros, Pierre, Smith, Denise, Dawe, David, Ellis, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560862/
https://www.ncbi.nlm.nih.gov/pubmed/31186068
http://dx.doi.org/10.1186/s13643-019-1047-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6560862/
https://www.ncbi.nlm.nih.gov/pubmed/31186068
http://dx.doi.org/10.1186/s13643-019-1047-z

Ejemplares similares